CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit)

N/A

Report date: 2026/04/30 20:00:20

Base Information

Drug NameCD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit)
Drug Alias NameCD30biAb-AATC(The Medical College Of Wisconsin Nonprofit)Anti-CD30 Bispecific Antibody-armed Anti-CD3-Activated Autologous T-cells(The Medical College Of Wisconsin Nonprofit)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > T cell engagersBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Tumor necrosis factor receptor superfamily member 8Anti-CD3
TargetsTumor necrosis factor receptor superfamily member 8T cell surface glycoprotein CD3
Therapy Area/IndicationsLymphoma, T-Cell, CutaneousLymphoma, Large-Cell, AnaplasticLymphoma, B-Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Medical College Of Wisconsin Nonprofit
China Registration ClassN/A

Develop Information

Active CompaniesThe Medical College Of Wisconsin Nonprofit
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell, CutaneousLymphoma, Large-Cell, AnaplasticLymphoma, B-Cell +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A